SEARCH

SEARCH BY CITATION

Literature Cited

  • 1
    Low D, O'Leary R, Pujar NS. Future of antibody purification. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;848:4863.
  • 2
    Langer E. Downstream factors that will continue to constrain manufacturing through 2013. BioProcessing J. 2009;8:2226.
  • 3
    Pujar NS, Low D, O'Leary R. Antibody purification: drivers of change. In: Gottschalk U, editor. Process Scale Purification of Antibodies. New Jersey: Wiley; 2009:407426.
  • 4
    Farid SS. Process economic drivers in industrial monoclonal antibody manufacture. In: Gottschalk U, editor. Process Scale Purification of Antibodies. New Jersey: Wiley; 2009:239261.
  • 5
    Kelley B. Very large scale monoclonal antibody purification: the case for conventional unit operations. Biotechnol Prog. 2007;23:9951008.
  • 6
    Kelley B. Industrialization of mAb production technology: the bioprocessing industry at a crossroads. mAbs. 2009;1:443452.
  • 7
    Farid SS, Washbrook J, Titchener-Hooker NJ. Decision-support tool for assessing biomanufacturing strategies under uncertainty: stainless steel versus disposable equipment for clinical trial material preparation. Biotechnol Prog. 2005;21:486497.
  • 8
    Farid SS, Washbrook J, Titchener-Hooker NJ. Modelling biopharmaceutical manufacture: design and implementation of SimBiopharma. Comput Chem Eng. 2007;31:11411158.
  • 9
    Lim AC, Zhou Y, Washbrook J, Sinclair A, Fish B, Francis R, Titchener-Hooker NJ, Farid SS. Application of a decision-support tool to assess pooling strategies in perfusion culture processes under uncertainty. Biotechnol Prog. 2005;21:12311242.
  • 10
    Lim AC, Washbrook J, Titchener-Hooker NJ, Farid SS. A computer-aided approach to compare the production economics of fed-batch and perfusion culture under uncertainty. Biotechnol Bioeng. 2006;93:687697.
  • 11
    Chhatre S, Jones C, Francis R, O'Donovan K, Titchener-Hooker NJ, Newcombe A Keshavarz-Moore E. The integrated simulation and assessment of the impacts of process change in biotherapeutic antibody production. Biotechnol Prog. 2006;23:16121620.
  • 12
    Joseph JR, Sinclair A, Tichener-Hooker NJ, Zhou Y. A framework for assessing the solutions in chromatographic process design and operation for large-scale manufacture. J Chem Technol Biotechnol. 2006;81:10091020.
  • 13
    Chhatre S, Thillaivinayagalingam P, Francis R, Titchener-Hooker NJ, Newcombe A Keshavarz-Moore E. Decision-support software for the industrial-scale chromatographic purification of antibodies. Biotechnol Prog. 2007;23:888894.
  • 14
    Stonier A, Simaria AS, Smith M, Farid SS. Decisional tool to assess current and future process robustness in an antibody purification facility. Biotechnol Prog. 2012;28:10191028.
  • 15
    Papageorgiou LG, Rotstein GE, Shah N. Strategic supply chain optimization for the pharmaceutical industries. Ind Eng Chem Res. 2001;40:275286.
  • 16
    Levis AA, Papageorgiou LG. A hierarchical solution approach for multi-site capacity planning under uncertainty in the pharmaceutical industry. Comput Chem Eng. 2004;28:707725.
  • 17
    Lakhdar K, Zhou Y, Savery J, Titchener-Hooker N J, Papageorgiou LG. Medium term planning of biopharmaceutical manufacture using mathematical programming. Biotechnol Prog. 2005;21:14781489.
  • 18
    Lakhdar K, Savery J, Papageorgiou LG, Farid SS. Multiobjective long-term planning of biopharmaceutical manufacturing facilities. Biotechnol Prog. 2007;23:13831393.
  • 19
    Vasquez-Alvarez E, Pinto JM. Efficient MILP formulations for the optimal synthesis of chromatographic protein purification processes. J Biotechnol. 2004;110:295311.
  • 20
    Simeonidis E, Pinto JM, Lienqueo ME, Tsoka S, Papageorgiou LG. MINLP models for the synthesis of optimal peptide tags and downstream protein processing. Biotechnol Prog. 2005;21:875884.
  • 21
    Natali JM, Pinto JM, Papageorgiou LG. Efficient MILP formulations for the simultaneous optimal peptide tag design and downstream processing synthesis. AIChE J. 2009;55:23032317.
  • 22
    Vasquez-Alvarez E, Pinto JM. A mixed integer linear programing model for the optimal synthesis of protein purification processes with product loss. Chem Biochem Eng Q. 2003;17:7784.
  • 23
    Polykarpou EM, Dalby PA, Papageorgiou LG. Optimal synthesis of chromatographic trains for downstream protein processing. Biotechnol Prog. 2011;27:16531660.
  • 24
    Polykarpou EM, Dalby PA, Papageorgiou LG. A novel efficient optimisation system for purification process synthesis. Biochem Eng J. 2012;67:186193.
  • 25
    Polykarpou EM, Dalby PA, Papageorgiou LG. An MILP formulation for the synthesis of protein purification processes. Chem Eng Res Des. 2012;90:12621270.
  • 26
    Simaria AS, Turner R, Farid SS. A multi-level metaheuristic algorithm to optimise antibody purification processes at the bioprocess business interface. Biochem Eng J. 2012;69:144154.
  • 27
    Allmendinger R, Simaria AS, Farid SS. Efficient discovery of chromatography equipment sizing strategies for antibody purification processes using evolutionary computing. Parallel Problem Solving Nature PPSN XII. 2012;7492:468477.
  • 28
    Stonier A, Pain D, Westlake A, Hutchinson N, Thornhill N, Farid SS. Integration of stochastic simulation with multivariate analysis: short-term facility fit prediction. Biotechnol Prog. 2013;29:368377.
  • 29
    Brooke A, Kendrick D, Meeraus A, Raman R. GAMS—A User's Guide. Washington, D.C.: GAMS Development Corporation; 2012.